Skip to content

Study · Non-randomized trial · 1993

8 results

Comparison of the effects of recombinant human insulin-like growth factor-I and insulin on glucose and leucine kinetics in humans.

Laager R, Ninnis R, Keller U

The Journal of clinical investigation1 Oct 1993Cited by 57 (Europe PMC)

PMID8408642 (opens in a new tab)PMCIDPMC288356 (opens in a new tab)DOI10.1172/jci116783 (opens in a new tab)PepBankPUB-08408642
Source linkPubMedAsk about this study
Jump to 8 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study8

8 results from studies that gave the peptide. 8 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    High-dose IGF-I increased glucose disappearance more than insulin in fasted normal subjects.

    In plain wordsIn fasted normal subjects, high-dose IGF-I increased glucose uptake more than insulin.

    Peptide
    IGF-1 (mecasermin)
    Outcome
    IncreaseGlucose disappearance
    Study

    n: not reported in source

    Comparator
    Insulin
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    30 micrograms/kg per h · infusion · 8 hAs given in this study (human).

    Measurements

    Glucose rate of disappearance, increase from baseline
    239%
    High dose IGF-I
    Glucose rate of disappearance, increase from baseline
    197%
    High dose insulin
    Reported +/- term for Glucose rate of disappearance, increase from baseline
    16%
    High dose IGF-I; uncertainty type not stated in the summary
    Reported +/- term for Glucose rate of disappearance, increase from baseline
    18%
    High dose insulin; uncertainty type not stated in the summary
    P value for Glucose rate of disappearance, increase from baseline
    0.021 dimensionless
    High dose IGF-I versus high dose insulin

    Source sentences

    Summary
    Glucose rate of disappearance (measured by [6,6-D2]-glucose infusions) increased from baseline by 239 +/- 16% during high dose IGF-I vs 197 +/- 18% during insulin (P = 0.021 vs IGF-I).
    2 context sentences
    Summary · context
    To compare the metabolic effects of elevated plasma concentrations of IGF-I and insulin, overnight-fasted normal subjects were studied twice, once receiving IGF-I and once insulin at doses that resulted in identical increases in glucose uptake during 8-h euglycemic clamping.
    Summary · context
    Recombinant human IGF-I or insulin were infused in one group at high doses (30 micrograms/kg per h IGF-I or 0.23 nmol/kg per h insulin) and in another group at low doses (5 micrograms/kg per h IGF-I or 0.04 nmol/kg per h insulin).
  2. 02HumanNon-randomized trialEfficacy outcome

    High-dose IGF-I suppressed hepatic glucose production less than insulin in fasted normal subjects.

    In plain wordsIn fasted normal subjects, high-dose IGF-I reduced liver glucose production less than insulin.

    Peptide
    IGF-1 (mecasermin)
    Outcome
    IncreaseHepatic glucose production
    Study

    n: not reported in source

    Comparator
    Insulin
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    30 micrograms/kg per h · infusion · 8 hAs given in this study (human).

    Measurements

    Hepatic glucose production decrease
    37%
    High dose IGF-I
    Hepatic glucose production decrease
    89%
    High dose insulin
    Reported +/- term for Hepatic glucose production decrease
    6%
    High dose IGF-I; uncertainty type not stated in the summary
    Reported +/- term for Hepatic glucose production decrease
    13%
    High dose insulin; uncertainty type not stated in the summary
    P value for Hepatic glucose production decrease
    0.0028 dimensionless
    High dose IGF-I versus high dose insulin

    Source sentences

    Summary
    Hepatic glucose production decreased by 37 +/- 6% during high dose IGF-I vs 89 +/- 13% during insulin (P = 0.0028 vs IGF-I).
    2 context sentences
    Summary · context
    To compare the metabolic effects of elevated plasma concentrations of IGF-I and insulin, overnight-fasted normal subjects were studied twice, once receiving IGF-I and once insulin at doses that resulted in identical increases in glucose uptake during 8-h euglycemic clamping.
    Summary · context
    Recombinant human IGF-I or insulin were infused in one group at high doses (30 micrograms/kg per h IGF-I or 0.23 nmol/kg per h insulin) and in another group at low doses (5 micrograms/kg per h IGF-I or 0.04 nmol/kg per h insulin).
  3. 03HumanNon-randomized trialEfficacy outcome

    High-dose IGF-I suppressed whole-body leucine flux more than insulin in fasted normal subjects.

    In plain wordsIn fasted normal subjects, high-dose IGF-I reduced protein breakdown more than insulin.

    Peptide
    IGF-1 (mecasermin)
    Outcome
    DecreaseWhole-body leucine flux
    Study

    n: not reported in source

    Comparator
    Insulin
    Outcome group
    Protein and amino acid metabolism · Metabolic and weight
    Studied dose
    30 micrograms/kg per h · infusion · 8 hAs given in this study (human).

    Measurements

    Whole body leucine flux suppression
    42%
    High dose IGF-I
    Whole body leucine flux suppression
    32%
    High dose insulin
    Reported +/- term for Whole body leucine flux suppression
    4%
    High dose IGF-I; uncertainty type not stated in the summary
    Reported +/- term for Whole body leucine flux suppression
    3%
    High dose insulin; uncertainty type not stated in the summary
    P value for Whole body leucine flux suppression
    0.0082 dimensionless
    High dose IGF-I versus high dose insulin

    Source sentences

    Summary
    IGF-I suppressed whole body leucine flux ([1-13C]-leucine infusion technique) more than insulin (42 +/- 4 vs 32 +/- 3% during high doses, P = 0.0082).
    2 context sentences
    Summary · context
    To compare the metabolic effects of elevated plasma concentrations of IGF-I and insulin, overnight-fasted normal subjects were studied twice, once receiving IGF-I and once insulin at doses that resulted in identical increases in glucose uptake during 8-h euglycemic clamping.
    Summary · context
    Recombinant human IGF-I or insulin were infused in one group at high doses (30 micrograms/kg per h IGF-I or 0.23 nmol/kg per h insulin) and in another group at low doses (5 micrograms/kg per h IGF-I or 0.04 nmol/kg per h insulin).
  4. 04HumanNon-randomized trialEfficacy outcome

    High-dose IGF-I reduced leucine oxidation more than insulin in fasted normal subjects.

    In plain wordsIn fasted normal subjects, high-dose IGF-I reduced leucine breakdown more than insulin.

    Peptide
    IGF-1 (mecasermin)
    Outcome
    DecreaseLeucine oxidation
    Study

    n: not reported in source

    Comparator
    Insulin
    Outcome group
    Protein and amino acid metabolism · Metabolic and weight
    Studied dose
    30 micrograms/kg per h · infusion · 8 hAs given in this study (human).

    Measurements

    Leucine oxidation rate decrease
    55%
    High dose IGF-I
    Leucine oxidation rate decrease
    32%
    High dose insulin
    Reported +/- term for Leucine oxidation rate decrease
    4%
    High dose IGF-I; uncertainty type not stated in the summary
    Reported +/- term for Leucine oxidation rate decrease
    6%
    High dose insulin; uncertainty type not stated in the summary
    P value for Leucine oxidation rate decrease
    0.0001 dimensionless
    High dose IGF-I versus high dose insulin

    Source sentences

    Summary
    Leucine oxidation rate decreased during high dose IGF-I more than during insulin (55 +/- 4 vs 32 +/- 6%, P = 0.0001).
    2 context sentences
    Summary · context
    To compare the metabolic effects of elevated plasma concentrations of IGF-I and insulin, overnight-fasted normal subjects were studied twice, once receiving IGF-I and once insulin at doses that resulted in identical increases in glucose uptake during 8-h euglycemic clamping.
    Summary · context
    Recombinant human IGF-I or insulin were infused in one group at high doses (30 micrograms/kg per h IGF-I or 0.23 nmol/kg per h insulin) and in another group at low doses (5 micrograms/kg per h IGF-I or 0.04 nmol/kg per h insulin).
  5. 05HumanNon-randomized trialEfficacy outcome

    IGF-I and insulin produced similar decreases in free fatty acids in fasted normal subjects.

    In plain wordsIn fasted normal subjects, IGF-I and insulin reduced free fatty acids similarly.

    Peptide
    IGF-1 (mecasermin)
    Outcome
    No significant changeFree fatty acids
    Study

    n: not reported in source

    Comparator
    Insulin
    Outcome group
    Lipids · Metabolic and weight
    Studied dose
    Dose not stated · infusion · 8 hAs given in this study (human).

    Source sentences

    Summary
    The decreases of plasma concentrations of free fatty acids, acetoacetate, and beta-hydroxybutyrate after 8 h of IGF-I and insulin administration were similar.
    2 context sentences
    Summary · context
    To compare the metabolic effects of elevated plasma concentrations of IGF-I and insulin, overnight-fasted normal subjects were studied twice, once receiving IGF-I and once insulin at doses that resulted in identical increases in glucose uptake during 8-h euglycemic clamping.
    Summary · context
    Recombinant human IGF-I or insulin were infused in one group at high doses (30 micrograms/kg per h IGF-I or 0.23 nmol/kg per h insulin) and in another group at low doses (5 micrograms/kg per h IGF-I or 0.04 nmol/kg per h insulin).
  6. 06HumanNon-randomized trialEfficacy outcome

    IGF-I and insulin produced similar decreases in acetoacetate in fasted normal subjects.

    In plain wordsIn fasted normal subjects, IGF-I and insulin reduced acetoacetate similarly.

    Peptide
    IGF-1 (mecasermin)
    Outcome
    No significant changeAcetoacetate
    Study

    n: not reported in source

    Comparator
    Insulin
    Outcome group
    Metabolic pathways and metabolomics · Metabolic and weight
    Studied dose
    Dose not stated · infusion · 8 hAs given in this study (human).

    Source sentences

    Summary
    The decreases of plasma concentrations of free fatty acids, acetoacetate, and beta-hydroxybutyrate after 8 h of IGF-I and insulin administration were similar.
    2 context sentences
    Summary · context
    To compare the metabolic effects of elevated plasma concentrations of IGF-I and insulin, overnight-fasted normal subjects were studied twice, once receiving IGF-I and once insulin at doses that resulted in identical increases in glucose uptake during 8-h euglycemic clamping.
    Summary · context
    Recombinant human IGF-I or insulin were infused in one group at high doses (30 micrograms/kg per h IGF-I or 0.23 nmol/kg per h insulin) and in another group at low doses (5 micrograms/kg per h IGF-I or 0.04 nmol/kg per h insulin).
  7. 07HumanNon-randomized trialEfficacy outcome

    IGF-I and insulin produced similar decreases in beta-hydroxybutyrate in fasted normal subjects.

    In plain wordsIn fasted normal subjects, IGF-I and insulin reduced beta-hydroxybutyrate similarly.

    Peptide
    IGF-1 (mecasermin)
    Outcome
    No significant changeBeta-hydroxybutyrate
    Study

    n: not reported in source

    Comparator
    Insulin
    Outcome group
    Metabolic pathways and metabolomics · Metabolic and weight
    Studied dose
    Dose not stated · infusion · 8 hAs given in this study (human).

    Source sentences

    Summary
    The decreases of plasma concentrations of free fatty acids, acetoacetate, and beta-hydroxybutyrate after 8 h of IGF-I and insulin administration were similar.
    2 context sentences
    Summary · context
    To compare the metabolic effects of elevated plasma concentrations of IGF-I and insulin, overnight-fasted normal subjects were studied twice, once receiving IGF-I and once insulin at doses that resulted in identical increases in glucose uptake during 8-h euglycemic clamping.
    Summary · context
    Recombinant human IGF-I or insulin were infused in one group at high doses (30 micrograms/kg per h IGF-I or 0.23 nmol/kg per h insulin) and in another group at low doses (5 micrograms/kg per h IGF-I or 0.04 nmol/kg per h insulin).
  8. 08HumanNon-randomized trialEfficacy outcome

    High-dose IGF-I reduced plasma C-peptide more than insulin in fasted normal subjects.

    In plain wordsIn fasted normal subjects, high-dose IGF-I reduced C-peptide more than insulin.

    Peptide
    IGF-1 (mecasermin)
    Outcome
    DecreaseC-peptide
    Study

    n: not reported in source

    Comparator
    Insulin
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    30 micrograms/kg per h · infusion · 8 hAs given in this study (human).

    Measurements

    Plasma C-peptide decrease
    57%
    High dose IGF-I
    Plasma C-peptide decrease
    36%
    High dose insulin
    Reported +/- term for Plasma C-peptide decrease
    4%
    High dose IGF-I; uncertainty type not stated in the summary
    Reported +/- term for Plasma C-peptide decrease
    6%
    High dose insulin; uncertainty type not stated in the summary
    P value for Plasma C-peptide decrease
    0.005 dimensionless
    High dose IGF-I versus high dose insulin

    Source sentences

    Summary
    Plasma C-peptide levels decreased by 57 +/- 4% during high doses of IGF-I vs 36 +/- 6% during insulin (P = 0.005 vs IGF-I).
    2 context sentences
    Summary · context
    To compare the metabolic effects of elevated plasma concentrations of IGF-I and insulin, overnight-fasted normal subjects were studied twice, once receiving IGF-I and once insulin at doses that resulted in identical increases in glucose uptake during 8-h euglycemic clamping.
    Summary · context
    Recombinant human IGF-I or insulin were infused in one group at high doses (30 micrograms/kg per h IGF-I or 0.23 nmol/kg per h insulin) and in another group at low doses (5 micrograms/kg per h IGF-I or 0.04 nmol/kg per h insulin).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    14 Oct 2026, 05:02 UTC

    Study results updated

  2. Version 1

    14 Oct 2026, 01:46 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.